Cointime

Proteon Therapeutics

company

About

Proteon Therapeutics is a biopharmaceutical company developing pharmaceuticals for patients with renal and vascular diseases.

  • Waltham,Massachusetts,United States
  • 11 - 50

Highlights

Stock Symbol
nasdaq:PRTO
Total Funding Amount
€21M $237.83M
Funding Rounds
10
Investors
20
Acquisition
1
Employee Profiles
2

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
€21M
Industries
Biotechnology,Medical,Pharmaceutical
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active
Stock Symbol
nasdaq:PRTO
Legal Name
Proteon Therapeutics, Inc.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.

The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.

Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures.

The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
10
€21M $237.83M
Proteon Therapeutics has raised a total of €21M $237.83M in funding over 2 rounds. Their latest funding was raised on Aug 10, 2021 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 10, 2021 Post-IPO Equity €21M 5 Aqua Spark
PFR Life Science
Nutreco 		— Detail
Jul 25, 2019 Grant — 1 European regional development fund (ERDF) — Detail
Jun 22, 2017 Post-IPO Equity $22M 1 Deepfield — Detail
Nov 25, 2014 IPO $70.30M — — — Detail
May 16, 2014 Series D $45M 13 Abingworth — Detail
Show More

Investors

Number of Lead Investors
Number of Investors
14
20
Proteon Therapeutics is funded by 20 investors. Aqua Spark and PFR Life Science are the most recent investors.
Investor Name Lead Investor Funding Round
Aqua Spark Yes Post-IPO Equity
PFR Life Science Yes Post-IPO Equity
Nutreco Yes Post-IPO Equity
European regional development fund (ERDF) Yes Grant
Deepfield Yes Post-IPO Equity
Abingworth Yes Series D
Montis Capital — Post-IPO Equity
Seventure Partners — Post-IPO Equity
Life Sciences Fund — Series D
Inbio Ventures — Series D
Show More

Employee Profiles

Number of Employee Profiles
2
Proteon Therapeutics has 2 current employee profiles, including Board member Hubert Birner
Hubert Birner
Board member
Stephen J. Hoffman
Board member

Acquisition

Proteon Therapeutics has acquired 1 organizations. Their most recent acquisition was Protara Therapeutics on Sep 23, 2019. They acquired Protara Therapeutics for 0.

Date Company Name
Industry Acquisition Type Price
Sep 23, 2019 Protara Therapeutics
Biotechnology merge — Detail
Cointime
เนื้อหา
บริษัท